Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy

Head and Neck

Volumn 33, Issue 10, 2011, Pages 1458-1466

  Kim, Yeon Joo ^a   Go, Heounjeong ^a   Wu, Hong Gyun ^a   Jeon, Yoon Kyung ^a   Park, Suk Won ^b   Lee, Seung Hee ^a  

^a Seoul National University   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

combined score; immunohistochemical staining; nasopharyngeal carcinoma; prognostic biomolecular markers; radiotherapy

Indexed keywords

CATHEPSIN D; CISPLATIN; CYCLOOXYGENASE 2; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NUCLEOSIDE DIPHOSPHATE KINASE NM23; PROTEIN P63; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; STAT5 PROTEIN; SYNDECAN 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE; STAINING;

ADULT; AGED; CARCINOMA; CATHEPSIN D; CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; CHEMOTHERAPY, ADJUVANT; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; EARLY GROWTH RESPONSE PROTEIN 1; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RADIOTHERAPY, INTENSITY-MODULATED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RNA-BINDING PROTEINS; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; SYNDECAN-1; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 80052999263     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21611     Document Type: Article

References (35)

1. Parkin DM WS, Ferlay J, Raymond L, Young J,. Cancer incidence in five continents. IARC 1997; 7: 814-815.
2. Ministry for Heath WaFA. Annual report of cancer incidence (2005) and survival (1993-2005) in Korea. 2005.
3. Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E,. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 1994; 21: 382-397.
4. Han L, Lin SJ, Pan JJ, et al. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Chin J Cancer 2010; 29: 145-150.
5. Chua DT, Nicholls JM, Sham JS, Au GK,. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 11-20.
6. Shi W, Pataki I, MacMillan C, et al. Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer 2002; 94: 1997-2006.
7. Su CK, Wang CC,. Prognostic value of Chinese race in nasopharyngeal cancer. Int J Radiat Oncol Biol Phys 2002; 54: 752-758.
8. Kim S, Grandis JR, Rinaldo A, Takes RP, Ferlito A,. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck 2008; 30: 667-674.
9. Ma BB, Poon TC, To KF, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma-a prospective study. Head Neck 2003; 25: 864-872.
10. Leong JL, Loh KS, Putti TC, Goh BC, Tan LK,. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 2004; 114: 153-157.
11. Qian CN, Guo X, Cao B, et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 2002; 62: 589-596.
12. Chen WC, McBride WH, Chen SM, et al. Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies. Head Neck 2005; 27: 503-512.
13. Guo X, Min HQ, Zeng MS, et al. nm23-H1 expression in nasopharyngeal carcinoma: correlation with clinical outcome. Int J Cancer 1998; 79: 596-600.
14. Taheri-Kadkhoda Z, Magnusson B, Svensson M, Mercke C, Bjork-Eriksson T,. Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. Head Neck 2009; 31: 482-492.
15. Roychowdhury DF, Tseng A Jr, Fu KK, Weinburg V, Weidner N,. New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. Cancer 1996; 77: 1419-1426.
16. Masuda M, Shinokuma A, Hirakawa N, Nakashima T, Komiyama S,. Expression of bcl-2-, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment. Head Neck 1998; 20: 640-644.
17. Hsiao JR, Jin YT, Tsai ST, Shiau AL, Wu CL, Su WC,. Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 2003; 89: 344-349.
18. Guo C, Pan ZG, Li DJ, et al. The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection. J Transl Med 2006; 4: 23-36.
19. Chen CL, Ou DL,. Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis. Hum Pathol 2006; 37: 1279-1285.
20. Adamson ED, Mercola D,. Egr1 transcription factor: multiple roles in prostate tumor cell growth and survival. Tumour Biol 2002; 23: 93-102.
21. Cheng AL, Huang WG, Chen ZC, et al. Identificating cathepsin D as a biomarker for differentiation and prognosis of nasopharyngeal carcinoma by laser capture microdissection and proteomic analysis. J Proteome Res 2008; 7: 2415-2426.
22. Kim KB WH, Park SW, Kim CJ, Park CI,. Expression of cyclooxygenase (COX-2) as a prognostic factor in nasopharyngeal cancer. Cancer Res Treat 2004; 36: 187-191.
23. Heng DM, Wee J, Fong KW, et al. Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer 1999; 86: 1912-1920.
24. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-1317.
25. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005; 23: 6730-6738.
26. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006; 64: 47-56.
27. Benvenuti S, Comoglio PM,. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007; 213: 316-325.
28. Fang WY, Liu TF, Xie WB, et al. Reexploring the possible roles of some genes associated with nasopharyngeal carcinoma using microarray-based detection. Acta Biochim Biophys Sin (Shanghai) 2005; 37: 541-546.
29. Brzoska E, Grabowska I,. Syndecans in cell adhesion and differentiation. Postepy Biochem 2005; 51: 52-59.
30. Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003; 98: 474-483.
31. Chen C-L, Ou D-L,. Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis. Hum Pathol 2006; 37: 1279-1285.
32. Anttonen A, Kajanti M, Heikkila P, Jalkanen M, Joensuu H,. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 1999; 79: 558-564.
33. Dawson CW, Rickinson AB, Young LS,. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990; 344: 777-780.
34. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E,. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389-399.
35. Viswanathan SR, Powers JT, Einhorn W, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009; 41: 843-848.